Law360, New York (August 05, 2009) -- A federal appeals court has upheld a ruling that invalidated the patent for Bayer Schering Pharma AG's oral contraceptive Yasmin in a dispute with Barr Laboratories Inc. over a generic version of the drug.
In a 2-1 ruling, the U.S. Court of Appeals for the Federal Circuit found that the patent was invalid for obviousness, affirming a ruling that led Bayer to enter into...
